Haizheng pharmaceutical 1.1 Alzheimer's treatment drug AD35 is expected to be approved clinically
-
Last Update: 2015-06-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the information on CFDA's website on June 5, the application status of Haizheng Pharmaceutical (600267 SH) 1.1 new chemical medicine ad-35 and ad-35 tablets changed to "certificate preparation completed - approved document", which is expected to be approved clinically People in the Securities Department of the company responded that they had not yet received the company's notice on the approval Earlier, the company pointed out that the application for ad-35, a new Alzheimer's drug, was approved in July 2014 in the United States; the application for phase I clinical treatment was completed in 2013 in China, and the information is being supplemented, and it is expected that Q1 in 2015 will be approved According to the public data, Alzheimer's disease, also known as Alzheimer's disease, is a fatal neurodegenerative disease with progressive development Its clinical manifestations are continuous deterioration of cognitive and memory functions, progressive decline of daily living ability, and various neuropsychological symptoms and behavioral disorders According to the prevalence study, the number of Alzheimer's cases in the United States in 2000 was 4.5 million, and the percentage of Alzheimer's patients will increase twice every five years of age Haizheng pharmaceutical is a leading API manufacturer in China, and one of the largest production bases of antibiotics and anti-tumor drugs in China At present, it is transforming to high-end preparations.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
